2019 Q1 SEC Filing Summary
Filing identity: The supplied filing is EyeGate Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended March 31, 2019, although the request metadata identifies Kiora Pharmaceuticals, Inc. The filing reports 45,575,737 common shares outstanding at May 6, 2019.
Business Context and Reporting Period
EyeGate is a clinical-stage ophthalmic pharmaceutical company developing CMHA-S-based products, including EyeGate Ocular Bandage Gel, and the EGP-437 dexamethasone iontophoresis combination product. The unaudited financial statements cover the three months ended March 31, 2019, with comparison to the three months ended March 31, 2018.
The company remains pre-commercial and has historically generated limited revenue, incurred operating losses, and relied on equity financings, license payments, grants, and collaborations.
Financial Performance and Position
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| Collaboration revenue | $2.686 million | $1.096 million | +$1.590 million |
| Research and development expense | $0.721 million | $2.521 million | -$1.800 million |
| General and administrative expense | $1.136 million | $0.954 million | +$0.182 million |
| Total operating expenses | $1.857 million | $3.475 million | -$1.618 million |
| Operating income (loss) | $0.829 million | $(2.379) million | +$3.208 million |
| Net income (loss) | $0.871 million | $(2.379) million | +$3.250 million |
| Net income (loss) per diluted share | $0.01 | $(0.14) | Improved |
| Net cash used in operating activities | $(2.147) million | $(4.115) million | Cash use decreased |
Q1 2019 operating and net margins were approximately 30.9% and 32.4%, respectively, but these margins were driven by a one-time recognition of deferred collaboration revenue rather than recurring product sales.
- Cash and cash equivalents were $5.856 million at March 31, 2019, compared with $8.004 million at December 31, 2018. Including restricted cash, total cash was $5.901 million.
- Total assets were $12.439 million and total liabilities were $2.400 million at March 31, 2019.
- Accumulated deficit was $92.279 million.
- The company reported no indebtedness other than trade and accounts payable and ordinary-course capital financing obligations. Non-current liabilities included $1.210 million of contingent consideration and $0.270 million of deferred tax liabilities.
- Stock-based compensation expense was $0.233 million, compared with $0.146 million in Q1 2018.
Material Changes Versus the Prior Comparable Period
- Revenue increased because the company recognized $2.686 million of previously deferred revenue after Bausch Health Companies terminated two license agreements effective March 14, 2019.
- All remaining deferred revenue under those agreements was recognized because the termination eliminated the company’s remaining performance obligations. No further revenue is expected from those agreements.
- R&D expense declined primarily because of reduced clinical activity and chemistry, manufacturing, and controls work related to EGP-437, together with lower personnel costs.
- G&A expense increased because of higher personnel-related and corporate costs, partly offset by lower legal and other public-company fees.
- The company adopted the new lease accounting standard on January 1, 2019, recording approximately $0.137 million of right-of-use assets and corresponding lease liabilities.
- Outstanding warrants increased substantially versus Q1 2018, reaching 40.844 million warrants at March 31, 2019, with a weighted-average exercise price of $1.00. Series C preferred stock was convertible into 12.788 million common shares, and 2.777 million stock options were outstanding.
Outlook, Risks, Contingencies, and Unusual Items
Management expects continued significant expenses and operating losses as it advances EyeGate OBG and evaluates strategic options for EGP-437. The company stated that its EGP-437 Phase 2b cataract study did not achieve statistically significant co-primary endpoints and that its Phase 3 uveitis study did not demonstrate non-inferiority to the control treatment.
Management projected that cash on hand would fund planned operations through October 31, 2019, subject to changes in spending. The filing states that additional capital will be required through equity or debt financing, licensing agreements, collaborations, or grants. Management concluded that recurring losses and financing needs create substantial doubt about the company’s ability to continue as a going concern.
- On May 3, 2019, the company filed an S-3 registration statement for up to $50 million of securities; it remained under SEC review and had not been declared effective.
- Nasdaq notified the company that its stock remained below the $1.00 minimum bid-price requirement. The company requested a hearing and presented its compliance plan on May 2, 2019; the Nasdaq Hearings Panel had not yet issued its decision.
- Operating leases required approximately $101,500 of remaining 2019 payments. Licensing commitments totaled approximately $347,500, for aggregate disclosed contractual obligations of $449,000.
- Bausch Health’s termination returned the EGP-437 rights to EyeGate but also ended the associated collaboration and future revenue opportunity.
- The company disclosed no material legal proceedings, no material off-balance-sheet arrangements, and no material changes to previously disclosed risk factors.
Important Facts for Investors to Verify
- Confirm the issuer identity: the filing text is for EyeGate Pharmaceuticals, Inc., not Kiora Pharmaceuticals, Inc.
- Determine whether the reported Q1 profit is understood as non-recurring deferred-license revenue rather than evidence of commercial profitability.
- Monitor cash consumption, financing activity, and the stated October 31, 2019 cash runway.
- Check the effectiveness and utilization of the proposed $50 million S-3 shelf registration.
- Verify the Nasdaq Hearings Panel decision and the company’s continued listing status.
- Assess dilution risk from 40.844 million warrants, 12.788 million shares issuable upon conversion of Series C preferred stock, and 2.777 million options.
- Track regulatory and clinical progress for EyeGate OBG and any strategic decision regarding EGP-437.